Document Classification

Section Type: RESULTS

Text: After the greater initial decrease (0-18 weeks) in glycated haemoglobin (HbA1c) with glipizide, the 18-104-week HbA1c coefficient of failure (CoF) was lower with dapagliflozin (0. 13 % / year) than with glipizide (0. 59 % / year), resulting in significant dapagliflozin versus glipizide differences of -0. 46 % / year (95 % CI -0. 60, -0. 33 ; p = 0. 0001) for CoF and -0. 18 % (-2. 0 mmol/mol) [95 % CI -0. 33 (-3. 6), -0. 03 (-0. 3) ; p = 0. 021] for 104-week HbA1c.